Myelodysplastic syndromes in the elderly

Cancer Control

Volumn 8, Issue 1, 2001, Pages 79-102

  Saba, Hussain I ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; APOPTOSIS; ARTICLE; BONE MARROW DISEASE; CYTOPENIA; DISEASE CLASSIFICATION; ELDERLY CARE; HEMATOPOIESIS; HUMAN; MYELODYSPLASTIC SYNDROME; REFRACTORY ANEMIA; SIDEROBLASTIC ANEMIA; WORLD HEALTH ORGANIZATION;

EID: 0035125357     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480100800112     Document Type: Article

References (134)

1. Myelodysplastic syndromes: Natural history and features of prognostic importance
2. Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: The cause-effect relationship
3. Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes
4. Biologic characteristics of patients with hypocellular myelodysplastic syndromes
5. Prevalence and causes of anaemia in a geriatric hospitalized population
6. Myelodysplastic syndromes in Thailand: A retrospective pathologic and clinical analysis of 117 cases
7. Prognostic factors of myelodysplastic syndromes: A simplified 3-D scoring system
8. Proposals for the classification of the myelodysplastic syndromes
9. Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held at Scottsdale, Arizona, on February 23-25, 1987
10. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997
11. Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system
12. Chronic myelomonocytic leukemia
13. Myelodysplastic syndromes: A forum for debate and discussion
14. Cytogenetics
15. Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value loc prognosis
16. Prognostic factors in myelodysplastic syndromes
17. Aberrant expression of p21RAS but not p120GAP is a common feature of myelodysplasia
18. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia
19. Codon 12 ras mutations in patients with myelodysplastic syndrome: Incidence and prognostic value
20. The nonrandom distribution of point mutations in leukaemia and myelodysplasia: A possible pointer to their aetiology
21. RAS and the myelodysplastic syndromes
22. RAS, RMS and p53 mutations and poor clinical outcome in myelodysplasias: A 10-year follow-up
23. Correlation of N-ras point mutations with specific chromosomal abnormalities in primary myelodysplastic syndrome
24. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients
25. Utility of the FAB classification for myelodysplastic syndromes: Investigation of prognostic factors in 237 cases
26. Prognostic factors in the myelodysplastic syndromes: Importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis
27. Myelodysplastic syndromes: A scoring system with prognostic significance
28. Myelodysplastic syndromes: A prognostic factor analysis of 221 untreated patients
29. International scoring system for evaluating prognosis in myelodysplastic syndromes
30. Prognostic factors and scoring systems in myelodysplastic syndromes: Recent advances in myelodysplastic syndromes
31. Modifications in the classification of primary myelodysplastic syndromes: The addition of a scoring system
32. NCCN practice guidelines for the myelodyplastic syndromes
33. Hemopoietic growth factors in myelodysplasia
34. Refractory anaemia with excess of myeloblasts in the bone marrow: A clinical trial of androgens in 90 patients
35. Danazol therapy in myelodysplasia
36. Danazol (DZ) treatment for myelodysplastic syndrome (MDS)
37. Differentiation of myeloid leukaemic cells: New possibilities for therapy
38. Response of preleukemic syndromes to continuous infusion of low-dose cytarabine
39. Evaluation of low dose Ara-C versus supportive care in the treatment of myelodysplastic syndromes: An intergroup study by the Eastern Cooperative Oncology Group and Southwest Oncology Group
40. A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome
41. N-(4-hydroxyphenyl) retinamide [4-HPR] therapy in myelodysplastic syndromes (MDS): Possible disease acceleration by retinoids
42. The myelodysplastic syndromes: Current approaches to therapy
43. 5-Aza-2′-deoxycytidine (decitabine) is an effective agent for the treatment of advanced myelodysplastic syndromes (MDS)
44. 5-Aza-2′deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemia and myelodysplastic syndromes: Past, present, and future trends
45. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes
46. Low-dose 5-Aza-2′-deoxycytidine, a DNA hypomethylating agent for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients
47. A randomized controlled trial of subcutaneous azacytidine (aza c) in patients with the myelodysplastic syndrome (MDS): A study of the Cancer and Leukemia Group B (CALGB)
48. The impact of 5-azacytidine on the quality of life of patients with the myelodysplastic syndrome (MDS) treated in a randomized phase III trial of the Cancer and Leukemia Group B (CALGB)
49. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score
50. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes
51. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS
52. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome
53. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes
54. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
55. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia
56. Effect of chemotherapy for the dysmyelopoietic syndrome
57. High-dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study
58. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes
59. Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine and prednisone (ROAP)
60. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes
61. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome
62. The role of intensive chemotherapy in myelodysplastic syndromes
63. The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromes
64. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine
65. Role of aggressive treatment strategies for myelodysplastic syndromes
66. Acute leukemic transformation in myelodysplastic syndrome
67. MDRI gene expression and treatment out-come in acute myeloid leukemia
68. Combination of quinine as a potential reversing agent with mitroxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study
69. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia
70. Phase I/II trial of cyclosporin as a chemotherapy-resistance modifier in acute leukemia
71. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin
72. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)
73. The myelodysplastic syndromes: Biology and implications for management
74. Autocrine secretion of GM-CSF in acute myeloblastic leukemia
75. Human recombinant multilineage colony stimulating factor (interleukin-3): Stimulator of acute myelocytic leukemia progenitor cells in vitro
76. Effects of recombinant human granulocytic-macrophage colony-stimulating factor in patients with myelodysplastic syndromes
77. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome
78. Subcutaneous granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndrome: Toxicity, pharmacokinetics, and hematological effects
79. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes: A phase I/II trial
80. Therapy of myelodysplastic syndromes (MDS) with GM-CSF
81. Randomized trial of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) versus observation in patients (pts) with myelodysplastic syndrome (MDS)
82. A randomized phase I/II study with recombinant human GM-CSF in patients (pts) with myelodysplastic syndromes at relatively low risk of developing acute leukemia
83. Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia
84. A randomized phase I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia
85. Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia
86. Effects of CSFs in preleukemia
87. Differential dose-related hematological effects of GM-CSF in pancytopenia: Evidence supporting the advantage of low-over high-dose administration in selected patients
88. Recurrent spleen enlargement during cyclic granulocyte macrophage colony stimulating factor therapy for myelodysplastic syndromes
89. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony stimulating factor: A phase I-II trial
90. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: A preliminary report
91. Hematologic and cytogenetic findings in myelodysplastic syndromes treated with recombinant human granulocyte colony-stimulating factor
92. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor
93. A phase II trial of recombinant human granulocyte colony stimulating factor in the myelodysplastic syndromes
94. Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor
95. Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS)
96. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes
97. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes
98. Treatment of myelodysplastic syndromes with recombinant human erythropoietin
99. Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile?
100. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin
101. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy
102. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients
103. Is cytokine therapy superior to chemotherapy in the management of acute myelocytic leukemia evolving from myelodysplasia
104. Treatment of the myelodysplastic syndromes: An updated Japanese experience
105. In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients
106. Interleukin-2 therapy for myelodysplastic syndrome: Does it work?
107. A phase II trial of interleukin-2 in myelodysplastic syndromes
108. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia
109. Recombinant human interleukin-8 restores function in neutrophils from patients with myelodysplastic syndromes without stimulating myeloid progenitor cells
110. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl
111. Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia
112. Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes
113. Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome
114. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors
115. Reducing the toxicity of anticancer therapy: New strategies
116. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
117. Poor response rate to a continuous schedule of amifostine therapy for "low/intermediate risk" myelodysplastic patients
118. Long-term improvement of hematopoiesis following cyclosporine treatment in a patient with myelodysplastic syndrome
119. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
120. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome
121. Antithymocyte globulin for patients with myelodysplastic syndrome
122. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles
123. Antithymocyte globulin for the treatment of patients with "low risk" myelodysplastic syndromes
124. Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes
125. Encouraging response to amifostine, pentoxifylline, ciprofloxacin, dexamethasone (A-PCD) +/- topotecan in patients with myelodysplastic syndromes
126. A new combination chemotherapy using topotecan, fludarabine, ARA-C and G-CSF for aggressive myelodysplastic syndromes and acute myelogenous leukemia in the elderly: Dose finding for topotecan study
127. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
128. Low-dose melphalan induces favourable responses in elderly patients with high risk myelodysplastic syndromes or secondary acute myeloid leukemia
129. Thalidomide is effective in the treatment of recurrent, refractory multiple myeloma
130. Thalidomide produces transfusion independence in patients with long standing refractory anemias and myelodysplastic syndromes (MDS)
131. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
132. US multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL)
133. Major hematologic response in a patient with myelodysplasia (MDS) to arsenic trioxide (ATO)
134. Phase II trial of arsenic trioxide (AS203) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML), blast crisis of CML, or myelodysplasia (MDS)